Sage Therapeutics: Results from the Phase 3 ROBIN Trial



Sage Therapeutics’ ROBIN trial

On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. The trial evaluated the safety, efficacy, and other pharmacological parameters of SAGE-217 in females with severe postpartum depression.

In the ROBIN trial, SAGE-217 met the clinical trial’s primary and secondary endpoints. In the trial, patients receiving SAFE-217 demonstrated a statistically significant improvement of 17.8 points in the HAMD-17 (Hamilton Rating Scale for Depression) score. Patients receiving a placebo had a score of 13.6 points. In the trial, 45% of the patients receiving SAGE-217 achieved remission—compared to 23% of the patients receiving a placebo. To learn more about the clinical trial results, read Sage Therapeutics’ press release.

The success in the clinical trial will help Sage Therapeutics with supportive data for submitting a New Drug Application to different regulatory authorities across the world to commercialize the drug.

Article continues below advertisement

Stock performance

On January 4, Sage Therapeutics’ stock price closed at $97.51, which represents ~9.16% growth from its previous close of $89.33 on January 3. On December 31, Sage Therapeutics’ stock price grew ~7.64% to $95.76 from its previous close of $88.99 on December 28.

On January 4, the company’s stock price closed at $97.51, which is ~51% below its 52-week high of $195.97 on January 31, 2018. Sage Therapeutics hit its 52-week low of $79.88 on December 24.

Analysts’ recommendations

Among the 17 analysts tracking Sage Therapeutics in January, eight recommended a “strong buy,” eight recommended a “buy,” and one recommended a “sell.”

On January 7, Sage Therapeutics had a consensus 12-month target price of $200.13, which is an ~105.24% return on investment over the next 12 months.


More From Market Realist